Skip to main content

Advertisement

SpringerLink
Log in

Development and validation of a liquid chromatography–tandem mass spectrometry method for the simultaneous quantification of tamoxifen, anastrozole, and letrozole in human plasma and its application to a clinical study

  • Original Paper
  • Published:
Analytical and Bioanalytical Chemistry Aims and scope Submit manuscript

Abstract

There is substantial evidence that circulating estrogens promote the proliferation of breast cancer. Consequently, adjuvant hormonal treatment strategies targeting estrogen action have been established. Such hormonal therapies include selective estrogen receptor modulators, such as tamoxifen, which interfere at the estrogen receptors directly, or non-steroidal aromatase inhibitors, such as anastrozole and letrozole, which inhibit estrogen synthesis through blocking the aromatase, a key enzyme of estrogen production. Despite considerable therapeutic success, in several cases, the use of these drugs is limited by side effects that have been described to significantly impair the adherence of patients to endocrine treatment. However, objective data concerning patient adherence and its clinical relevance are limited. One promising approach to check patient-reported adherence is drug monitoring in human plasma. Therefore, a liquid chromatography–tandem mass spectrometry method to determine the plasma concentrations of tamoxifen, anastrozole, and letrozole has been developed and fully validated according to guidelines for clinical and forensic toxicology. The validation criteria evaluated were selectivity, linearity, accuracy and precision, limit of quantification, recovery and matrix effects, sample stability, and carryover. The six-point calibration curves showed linearity over the range of concentrations from 25 to 500 ng/ml for tamoxifen, 5 to 200 ng/ml for anastrozole, and 10 to 300 ng/ml for letrozole. The intra- and inter-day precision and accuracies were always better than 15%. The validated procedure was successfully applied to a clinical study (Patient-Reported Outcomes in Breast Cancer Patients undergoing Endocrine Therapy, PRO-BETh). A major aim of PRO-BETh study is the comprehensive evaluation of adherence to treatment in pre- and post-menopausal women with breast cancer. Plasma samples of 310 breast cancer patients undergoing anti-estrogen therapy were analyzed. Eight samples did not contain a quantifiable amount of drug, strongly indicating non-adherence of the corresponding patients to adjuvant breast cancer treatment. Furthermore, plasma concentrations at the lower end of the observed plasma level distribution might represent a hint but not a confirmation for non-adherence in terms of non-daily and irregular intake of the prescribed drug.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Hortobagyi GN, de la Garza SJ, Pritchard K, Amadori D, Haidinger R, Hudis CA, Khaled H, Liu MC, Martin M, Namer M, O’Shaughnessy JA, Shen ZZ, Albain KS (2005) Clin Breast Cancer 6:391

    Article  Google Scholar 

  2. Hiscox S, Davies EL, Barrett-Lee P (2009) Maturitas 63:275

    Article  CAS  Google Scholar 

  3. Choueiri TK, Alemany CA, Bou-Jawde RM, Budd GT (2004) Clin Ther 26:1199

    Article  CAS  Google Scholar 

  4. Eisen A, Trudeau M, Shelley W, Messersmith H, Pritchard KI (2008) Cancer Treat Rev 34:157

    Article  CAS  Google Scholar 

  5. Hind D, Ward S, De NE, Simpson E, Carroll C, Wyld L (2007) Health Technol Assess 11:1

    Google Scholar 

  6. Musgrove EA, Sutherland RL (2009) Nat Rev Cancer 9:631

    Article  CAS  Google Scholar 

  7. Robinson E, Kimmick GG, Muss HB (1996) Drugs Aging 8:329

    Article  CAS  Google Scholar 

  8. Conte P, Frassoldati A (2007) Breast J 13:28

    Article  CAS  Google Scholar 

  9. Perez EA (2007) Ann Oncol 18(Suppl 8):viii26

    Google Scholar 

  10. Demissie S, Silliman RA, Lash TL (2001) J Clin Oncol 19:322

    CAS  Google Scholar 

  11. Fink AK, Gurwitz J, Rakowski W, Guadagnoli E, Silliman RA (2004) J Clin Oncol 22:3309

    Article  Google Scholar 

  12. Partridge AH, Wang PS, Winer EP, Avorn J (2003) J Clin Oncol 21:602

    Article  CAS  Google Scholar 

  13. Partridge AH (2006) Ann Oncol 17:183

    Article  CAS  Google Scholar 

  14. Ziller V, Kalder M, Albert US, Holzhauer W, Ziller M, Wagner U, Hadji P (2009) Ann Oncol 20:431

    Article  CAS  Google Scholar 

  15. Chlebowski RT, Geller ML (2006) Oncology 71:1

    CAS  Google Scholar 

  16. Ruddy K, Mayer E, Partridge A (2009) CA Cancer J Clin 59:56

    Article  Google Scholar 

  17. Hadji P (2010) Crit Rev Oncol Hematol 73:156

    Article  Google Scholar 

  18. Larson ME, Richards TM (2009) Clin Med Res 7:134

    Article  CAS  Google Scholar 

  19. Van Rossum AM, Bergshoeff AS, Fraaij PL, Hugen PW, Hartwig NG, Geelen SP, Wolfs TF, Weemaes CM, de Groot R, Burger DM (2002) Pediatr Infect Dis J 21:743

    Article  Google Scholar 

  20. Hiemke C (2008) Eur J Clin Pharmacol 64:159

    Article  Google Scholar 

  21. Touw DJ, Neef C, Thomson AH, Vinks AA (2005) Ther Drug Monit 27:10

    Article  CAS  Google Scholar 

  22. Gjerde J, Kisanga ER, Hauglid M, Holm PI, Mellgren G, Lien EA (2005) J Chromatogr A 1082:6

    Article  CAS  Google Scholar 

  23. Liu W, Zhang L, Chen S, Duan H, Chen X, Wei Z, Chen G (2009) Anal Chim Acta 631:47

    Article  CAS  Google Scholar 

  24. Murphy C, Fotsis T, Pantzar P, Adlercreutz H, Martin F (1987) J Steroid Biochem 26:547

    Article  CAS  Google Scholar 

  25. Teunissen SF, Rosing H, Koornstra RH, Linn SC, Schellens JH, Schinkel AH, Beijnen JH (2009) J Chromatogr B 877:2519

    Article  CAS  Google Scholar 

  26. Zweigenbaum J, Heinig K, Steinborner S, Wachs T, Henion J (1999) Anal Chem 71:2294

    Article  CAS  Google Scholar 

  27. de Voss D, Slee PH, Briggs RJ, Stevenson D (1998) Cancer Chemother Pharmacol 42:512

    Article  Google Scholar 

  28. Decensi A, Gandini S, Guerrieri-Gonzaga A, Johansson H, Manetti L, Bonanni B, Sandri MT, Barreca A, Costa A, Robertson C, Lien EA (1999) J Clin Oncol 17:2633

    CAS  Google Scholar 

  29. Dowsett M, Cuzick J, Howell A, Jackson I (2001) Br J Cancer 85:317

    Article  CAS  Google Scholar 

  30. Lee KH, Ward BA, Desta Z, Flockhart DA, Jones DR (2003) J Chromatogr B 791:245

    Article  CAS  Google Scholar 

  31. MacCallum J, Cummings J, Dixon JM, Miller WR (1996) J Chromatogr B 678:317

    Article  CAS  Google Scholar 

  32. Apostolou C, Dotsikas Y, Kousoulos C, Loukas YL (2008) J Pharm Biomed Anal 48:853

    Article  CAS  Google Scholar 

  33. Mendes GD, Hamamoto D, Ilha J, Pereira AS, De Nucci G (2007) J Chromatogr B 850:553

    Article  CAS  Google Scholar 

  34. Rodriguez-Flores J, Contento Salcedo AM, Villasenor Llerena MJ, Munoz FL (2008) Electrophoresis 29:811

    Article  CAS  Google Scholar 

  35. Ingle JN, Buzdar AU, Schaid DJ, Goetz MP, Batzler A, Robson ME, Northfelt DW, Olson JE, Perez EA, Desta Z, Weintraub RA, Williard CV, Flockhart DA, Weinshilboum RM (2010) Cancer Res 70:3278

    Article  CAS  Google Scholar 

  36. Dowsett M, Pfister C, Johnston SR, Miles DW, Houston SJ, Verbeek JA, Gundacker H, Sioufi A, Smith IE (1999) Clin Cancer Res 5:2338

    CAS  Google Scholar 

  37. Pfister CU, Martoni A, Zamagni C, Lelli G, De Braud F, Souppart C, Duval M, Hornberger U (2001) Biopharm Drug Dispos 22:191

    Article  CAS  Google Scholar 

  38. Peters FT, Drummer OH, Musshoff F (2007) Forensic Sci Int 165:216

    Article  CAS  Google Scholar 

  39. Oberacher H, Krajete A, Parson W, Huber CG (2000) J Chromatogr A 893:23

    Article  CAS  Google Scholar 

  40. Matuszewski BK, Constanzer ML, Chavez-Eng CM (2003) Anal Chem 75:3019

    Article  CAS  Google Scholar 

  41. Dadgar D, Burnett PE (1995) J Pharm Biomed Anal 14:23

    Article  CAS  Google Scholar 

  42. Koster E (2005) The Peak August 2005:5

    Google Scholar 

  43. Oberacher H, Pavlic M, Libiseller K, Schubert B, Sulyok M, Schuhmacher R, Csaszar E, Kofeler HC (2009) J Mass Spectrom 44:485

    Article  CAS  Google Scholar 

  44. Oberacher H, Pavlic M, Libiseller K, Schubert B, Sulyok M, Schuhmacher R, Csaszar E, Kofeler HC (2009) J Mass Spectrom 44:494

    Article  CAS  Google Scholar 

  45. Pfister CU, Duval M, Godbillon J, Gosset G, Gygax D, Marfil F, Sioufi A, Winkler B (1994) J Pharm Sci 83:520

    Article  CAS  Google Scholar 

  46. Buzdar AU, Robertson JF, Eiermann W, Nabholtz JM (2002) Cancer 95:2006

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Legal Medicine, Innsbruck Medical University, Muellerstrasse 44, 6020, Innsbruck, Austria

    Beate Beer, Birthe Schubert & Herbert Oberacher

  2. Department of General and Social Psychiatry, Innsbruck Medical University, Innsbruck, Austria

    Anne Oberguggenberger & Verena Meraner

  3. Department of Obstetrics and Gynecology, Innsbruck Medical University, Innsbruck, Austria

    Michael Hubalek

Authors
  1. Beate Beer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Birthe Schubert
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anne Oberguggenberger
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Verena Meraner
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Michael Hubalek
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Herbert Oberacher
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Herbert Oberacher.

Additional information

Beate Beer and Birthe Schubert have contributed equally to this study.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Beer, B., Schubert, B., Oberguggenberger, A. et al. Development and validation of a liquid chromatography–tandem mass spectrometry method for the simultaneous quantification of tamoxifen, anastrozole, and letrozole in human plasma and its application to a clinical study. Anal Bioanal Chem 398, 1791–1800 (2010). https://doi.org/10.1007/s00216-010-4075-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00216-010-4075-z

Keywords

Search

Navigation